R&D investments for neglected diseases can be sensitive to the economic goal of pharmaceutical companies

Kremer, 2006 Glennerster, 2006, Creating markets for vaccines, Innovations, 1, 67, 10.1162/itgg.2006.1.1.67 Maurer, 2006, Choosing the right incentive strategy for research and development in neglected diseases, Bull. World Health Org., 84, 376, 10.2471/BLT.06.029835 Acemoglu, 2004, Market size in innovation: evidence from the pharmaceutical industry, Q. J. Econ., 119, 1049, 10.1162/0033553041502144 Booth, 2004, Prospects for productivity, Nat. Rev. Drug Discov., 3, 451, 10.1038/nrd1384 Paul, 2010, How to improve R&D productivity: the pharmaceutical industry's grand challenge, Nat. Rev. Drug Discov., 9, 203, 10.1038/nrd3078 Munos, 2009, Lessons from 60 years of pharmaceutical innovation, Nat. Rev. Drug Discov., 8, 959, 10.1038/nrd2961 Dimitri, 2011, What constitutes an optimal portfolio of pharmaceutical compounds?, Clin. Pharmacol. Ther., 89, 304, 10.1038/clpt.2010.247 Henderson, 2001, Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research, J. Health Econ., 20, 1033, 10.1016/S0167-6296(01)00108-4 Ridley, 2006, Developing drugs for developing countries, Health Affairs, 25, 313, 10.1377/hlthaff.25.2.313 Dimitri, 2010, The economics of priority review vouchers, Drug Discov. Today, 15, 887, 10.1016/j.drudis.2010.08.008 Ridley, 2006, Introduction to European priority review vouchers to encourage development of new medicines for neglected diseases, The Lancet, 376, 1033 Osborne, 2004